Wells Fargo & Company reiterated their buy rating on shares of Celgene Corporation (NASDAQ:CELG) in a research note released on Friday. They currently have a $163.00 price target on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on CELG. Morgan Stanley downgraded shares of Celgene Corporation from an equal weight rating to an underweight rating and set a $120.00 target price for the company. in a research report on Thursday, October 5th. William Blair reiterated an outperform rating on shares of Celgene Corporation in a research report on Monday, June 26th. Cantor Fitzgerald reiterated a buy rating on shares of Celgene Corporation in a research report on Monday, August 28th. BTIG Research downgraded shares of Celgene Corporation from a buy rating to a neutral rating and increased their target price for the stock from $96.93 to $131.70 in a research report on Friday, June 30th. Finally, Vetr upgraded shares of Celgene Corporation from a hold rating to a buy rating and set a $146.58 target price for the company in a research report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of Buy and an average target price of $149.52.

Celgene Corporation (NASDAQ CELG) opened at 122.37 on Friday. Celgene Corporation has a one year low of $96.93 and a one year high of $147.17. The firm has a 50-day moving average price of $140.31 and a 200 day moving average price of $130.49. The firm has a market capitalization of $95.74 billion, a P/E ratio of 37.90 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion during the quarter, compared to analyst estimates of $3.23 billion. During the same quarter last year, the business posted $1.44 EPS. The company’s revenue was up 18.7% on a year-over-year basis. Equities research analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (CELG) Rating Reiterated by Wells Fargo & Company” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/10/24/celgene-corporation-celg-rating-reiterated-by-wells-fargo-company.html.

In other news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gilla Kaplan sold 7,500 shares of Celgene Corporation stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $134.52, for a total transaction of $1,008,900.00. Following the sale, the director now owns 76,301 shares in the company, valued at $10,264,010.52. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,233 shares of company stock worth $6,268,259. 0.95% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the company. Arcadia Investment Management Corp MI boosted its position in shares of Celgene Corporation by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares in the last quarter. Thompson Davis & CO. Inc. boosted its position in shares of Celgene Corporation by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Celgene Corporation during the 1st quarter valued at about $118,000. Motco boosted its position in shares of Celgene Corporation by 19.3% during the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 159 shares in the last quarter. Finally, Balentine LLC boosted its position in shares of Celgene Corporation by 83.5% during the 2nd quarter. Balentine LLC now owns 1,057 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 481 shares in the last quarter. Institutional investors and hedge funds own 79.23% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.